News|Articles|April 29, 2011
REMS Challenges Discussed
Advertisement
In late April, the Center for Business Intelligence (CBI) held a two-day forum on Drug Safety. The focus was REMS, the FDAs enforceable Risk Evaluation and Mitigation Strategy, and included discussions on REMS assessment, challenges, case studies, technology and more.
Applied Clinical Trials Editor Lisa Henderson attended the conference and blogged live. You can read the blogs by clicking the links below.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Drug Repurposing Through AI-Driven In-Silico Clinical Trials
2
Balancing Innovation and Compliance under New GCP Guidelines
3
ACT Brief: AI-Driven Repurposing Advances, GCP Adoption Challenges, and New CAR-T Milestone
4
Obesity Trials: Scaling Operations for High-Demand Therapeutics
5
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
